MONTREAL--(BUSINESS WIRE)--Soundbite Medical Solutions Inc. (SBMS), a medical device company dedicated to developing solutions for the interventional treatment of calcific peripheral and coronary arterial diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued US patent No. 11,000,880, entitled “Mechanical Waveguide Provided With A Marker Thereon”.
The patent is directed to a proprietary waveguide specially designed for the transmission of shock waves used in the treatment of cardiovascular disease. It covers the Active Wire, Soundbite’s proprietary guidewire, and the rest of the company's burgeoning product portfolio.
The patent is expected to expire no earlier than January 2039 and will provide key intellectual property protection for the Company's technology platform.
This is the third US patent to be issued around the approved Soundbite technology. A fourth US patent has recently been allowed. Soundbite continues to enhance its patent portfolio with additional patent applications that will broaden and strengthen its patent protection in other key markets throughout the world.
“Building a robust patent portfolio in the US and around the world, supported with clearances by regulatory bodies in the US, EU, Canada and eventually Japan strengthen our position in the cardiovascular intervention market,” said Lori Chmura, President & CEO of Soundbite.
The SoundBite® Crossing System – Peripheral (SCS-P) consists of the reusable SoundBite® Console, a single-use sterile SoundBite® Active Wire, and their respective accessories. SCS-P leverages Soundbite’s proprietary method to produce and safely deliver shock waves via guidewire platforms to selectively “micro- jackhammer” through calcified lesions.
“The cardiovascular community is primed for a new tool to help physicians treat these challenging and debilitating lesions safely and effectively,” said Dr. Martin Leon MD, Professor of Medicine at Columbia University Medical Center, Director of the Center for Interventional Vascular Therapy, Director of the Cardiac Catheterization Laboratories and Executive Board Member of the Columbia New York-Presbyterian Heart Valve Center, and Chair of Soundbite’s Medical Advisory Board. Dr. Leon added, “The progress that Soundbite has made in its patent work, as well as its FDA clearances, is promising.”
High calcium burden is present in up to 50% of PAD patients with severe claudication and in >65% of patients with CLI, especially in difficult to treat below-the-knee (BTK) disease. CTOs are encountered in up to 50% of PAD and CLI patients. CLI is associated with a high risk of lower limb amputation estimated in 10%–40% of patients at 6 months, especially in non-treatable patients.
About Soundbite Medical Solutions
Soundbite is a privately-held medical device company uniquely dedicated to developing meaningful solutions for the interventional treatment of calcific peripheral and coronary arterial diseases. Soundbite has developed and deployed a proprietary method to produce and safely deliver shock waves to calcified lesions using an array of devices to improve and transform the standard of care for treatment of patients suffering from calcified and occlusive cardiovascular disease. www.soundbitemedical.com.
For information on Soundbite Medical Solutions, please contact Ashkan Haghighat, PhD (ashkan.haghighat@soundbitemedical.com), Chief Business Officer, SoundBite Medical Solutions, 2300 Alfred Nobel, Montreal Québec H4S 2A4
Forward-Looking Statements This press release contains forward-looking statements and forward- looking information, or, collectively, forward-looking statements, within the meaning of applicable securities laws, that are based on our management’s belief and assumptions and on information currently available to our management. You can identify forward-looking statements by terms such as “may”, “will”, “should”, “could”, “would”, “outlook”, “believe”, “plan”, “envisage”, “anticipate”, “expect” and “estimate” or the negatives of these terms, or variations of them. Forward-looking statements are based upon a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond SoundBite Medical Solutions Inc.’s control that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward looking statements. Forward- looking statements reflect current expectations regarding future events and speak only as of the date of this press release and represent our expectations as of that date. We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances.
